UPCC 04325 TEMPUS PHOENIX HNSCC: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

Biomarker Study in Head and Neck Cancer

Enrolling By Invitation
18 years or above
All
Phase N/A
500 participants needed
1 Location

Brief description of study

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Head and Neck Squamous Cell Carcinoma
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • ≥18 years of age
  • Willing and able to provide informed consent
  • Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies
  • Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy
  • Must submit tumor tissue sample representative of current disease per laboratory manual

Exclusion Criteria:

  • Non-squamous histologies (eg, nasopharynx or salivary gland)
  • Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy
  • Tumors that are PD-L1 negative (CPS <1)
  • Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers
  • Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)

This study investigates head and neck squamous cell carcinoma (HNSCC). The purpose of this study is to understand the molecular characteristics of HNSCC by profiling biomarkers in tissue and blood samples from patients undergoing their usual care treatment.

Participants in this study will have their tissue and blood samples collected for molecular biomarker analysis during their standard treatment. This involves looking at the biological markers in the samples to understand the cancer better and potentially improve future treatments.

  • Who can participate: Participants must be 18 years or older, able to provide informed consent, have confirmed metastatic or unresectable recurrent HNSCC, and be starting first-line anti-PD1 or PDL1 therapy with a tumor tissue sample available.
  • Study details: Participants will undergo molecular biomarker profiling of their tissue and blood samples during their regular treatment. This study does not involve any changes to the participants' treatment plan.
Updated on 12 Jun 2026. Study ID: 24-1897
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator